Ann Oncol. 2024 Dec 17. IF: 56.7Tocilizumab and immune signatures for targeted management of cytokine release syndrome in immune checkpoint therapy.www.annalsofoncology.org/article/S0923-7534(24)04979-2/fulltext J Clin Oncol. 2024 Dec 17. IF: 42.1Breast Cancer Screening Interval: Effects of Proportions and Biases on Benefits.www.ascopubs.org/doi/10.1200/JCO-24-01965 J Clin Oncol. 2024 Dec 17. IF: 42.1Annual Versus Biennial Mammographic Screening.www.ascopubs.org/doi/10.1200/JCO-24-01902 J Clin Oncol. 2024 Dec 17. IF: 42.1Reply to: "Breast Cancer Screening Interval: Effects of Proportions and Biases on Benefits" and "Annual Versus Biennial Mammographic Screening".www.ascopubs.org/doi/10.1200/JCO-24-02373 Signal Transduct Target Ther. 2024 Dec 18;9:352. IF: 40.8Macrophages promote pre-metastatic niche formation of breast cancer through aryl hydrocarbon receptor activity.www.nature.com/articles/s41392-024-02042-5 Cell Metab. 2024 Dec 17. IF: 27.7Early downmodulation of tumor glycolysis predicts response to fasting-mimicking diet in triple-negative breast cancer patients.www.cell.com/cell-metabolism/fulltext/S1550-4131(24)00450-9 Nat Biomed Eng. 2024 Dec 17. IF: 26.8Deep profiling of gene expression across 18 human cancers.www.nature.com/articles/s41551-024-01290-8 ACS Nano. 2024 Dec 17. IF: 15.8Concurrent Detection of Protein and miRNA at the Single Extracellular Vesicle Level Using a Digital Dual CRISPR-Cas Assay.pubs.acs.org/doi/10.1021/acsnano.4c13557 Proc Natl Acad Sci U S A. 2024 Dec 17;121(52):e2416909121. IF: 9.4CXCL12 restricts tumor growth by suppressing the Ras, ERK1/2, c-Myc, and the immune checkpoint PD-L1 pathways.www.pnas.org/doi/10.1073/pnas.2416909121 J Cachexia Sarcopenia Muscle. 2024 Dec 17. IF: 9.4Low Skeletal Muscle Radiodensity Predicts Response to CDK4/6 Inhibitors Plus Aromatase Inhibitors in Advanced Breast Cancer.www.onlinelibrary.wiley.com/doi/10.1002/jcsm.13666
